International Journal of Alzheimer’s Disease / 2014 / Article / Fig 4

Research Article

Identification and Preclinical Pharmacology of the -Secretase Modulator BMS-869780

Figure 4

BMS-869780 had minimal effect on APP-CTF accumulation in vitro. H4-APPsw cell cultures were treated overnight with the indicated concentrations of BMS-869780, BMS-299897 or vehicle (0.1% DMSO). (a) Cells were harvested and analyzed by western blotting for APP-CTFα, APP-CTFβ, and GAPDH. Lane 1; culture treated with vehicle 0.1% DMSO. Lanes 2–5; cultures treated with BMS-869780 at 100 nM, 300 nM, 1000 nM, or 3000 nM, respectively. Lanes 6–8; cultures treated with BMS-299897 at 30 nM, 100 nM, or 300 nM, respectively. (b) Levels of Aβ1-42 (red; left -axis), Aβ1-40 (green; right -axis), and Aβ1-x (grey; right -axis) were quantified.
431858.fig.004a
(a)
431858.fig.004b
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.